CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented at the inaugural AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research. The oral presentation, taking place on September 20, 2025 in Denver, is titled “Gene-modified iPS-derived MSC restore a ‘Hot’ immune microenvironment in high-grade serous ovari ...